Monogalactosyl diacylglycerol, a replicative DNA polymerase inhibitor, from spinach enhances the anti-cell proliferation effect of gemcitabine in human pancreatic cancer cells

被引:23
作者
Akasaka, Hiroaki [1 ]
Sasaki, Ryohei [1 ]
Yoshida, Kenji [1 ]
Takayama, Izumi [1 ]
Yamaguchi, Toyofumi [2 ]
Yoshida, Hiromi [3 ]
Mizushina, Yoshiyuki [3 ,4 ]
机构
[1] Kobe Univ, Grad Sch Med, Div Radiat Oncol, Chuo Ku, Kobe, Hyogo 6500017, Japan
[2] Teikyo Univ Sci, Dept Life & Hlth Sci, Adachi Ku, Tokyo 1200045, Japan
[3] Kobe Gakuin Univ, Fac Nutr, Lab Food & Nutr Sci, Nishi Ku, Kobe, Hyogo 6512180, Japan
[4] Kobe Gakuin Univ, Cooperat Res Ctr Life Sci, Chuo Ku, Kobe, Hyogo 6508586, Japan
来源
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS | 2013年 / 1830卷 / 03期
基金
日本科学技术振兴机构;
关键词
Monogalactosyl diacylglycerol (MGDG); Gemcitabine (GEM); DNA polymerase (pol); Enzyme inhibitor; Anticancer; Apoptosis; RANDOMIZED-TRIAL; ALPHA; SURVIVAL; BETA; SULFOQUINOVOSYLDIACYLGLYCEROL; PANCREATICODUODENECTOMY; LYMPHADENECTOMY; PHYTOCHEMICALS; ADENOCARCINOMA; GLYCOLIPIDS;
D O I
10.1016/j.bbagen.2012.11.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Gemcitabine (GEM) is used to treat various carcinomas and represents an advance in pancreatic cancer treatment. In the screening for DNA polymerase (pol) inhibitors, a glycoglycerolipid, monogalactosyl diacylglycerol (MGDG), was isolated from spinach. Methods: Phosphorylated GEM derivatives were chemically synthesized. In vitro pot assay was performed according to our established methods. Cell viability was measured using MU assay. Results: Phosphotylated GEMs inhibition of mammalian pol activities assessed, with the order of their effect ranked as: GEM-5'-triphosphate (GEM-TP)>GEM-5'-diphosphate>GEM-5'-monophosphate>GEM. GEM suppressed growth in the human pancreatic cancer cell lines BxPC-3, MIAPaCa2 and PANC-1 although phosphorylated GEMs showed no effect. MGDG suppressed growth in these cell lines based on its selective inhibition of replicative pal species. Kinetic analysis showed that GEM-TP was a competitive inhibitor of pal a activity with nucleotide substrates, and MGDG was a noncompetitive inhibitor with nucleotide substrates. GEM combined with MGDG treatments revealed synergistic effects on the inhibition of DNA replicative pols alpha and gamma activities compared with GEM or MGDG alone. In cell growth suppression by GEM, pre-addition of MGDG significantly enhanced cell proliferation suppression, and the combination of these compounds was found to induce apoptosis. In contrast GEM-treated cells followed by MGDG addition did not influence cell growth. Conclusions: GEM/MGDG enhanced the growth suppression of cells based on the inhibition of pol activities. General significance: Spinach MGDG has great potential for development as an anticancer food compound and could be an effective clinical anticancer chemotherapy in combination with GEM. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:2517 / 2525
页数:9
相关论文
共 41 条
[1]  
[Anonymous], 1990, NATURE
[2]  
Bebenek K, 2004, ADV PROTEIN CHEM, V69, P137
[3]   Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].
Burris, HA ;
Moore, MJ ;
Andersen, J ;
Green, MR ;
Rothenberg, ML ;
Madiano, MR ;
Cripps, MC ;
Portenoy, RK ;
Storniolo, AM ;
Tarassoff, P ;
Nelson, R ;
Dorr, FA ;
Stephens, CD ;
VanHoff, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413
[4]   FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].
Conroy, Thierry ;
Desseigne, Francoise ;
Ychou, Marc ;
Bouche, Olivier ;
Guimbaud, Rosine ;
Becouarn, Yves ;
Adenis, Antoine ;
Raoul, Jean-Luc ;
Gourgou-Bourgade, Sophie ;
de la Fouchardiere, Christelle ;
Bennouna, Jaafar ;
Bachet, Jean-Baptiste ;
Khemissa-Akouz, Faiza ;
Pere-Verge, Denis ;
Delbaldo, Catherine ;
Assenat, Eric ;
Chauffert, Bruno ;
Michel, Pierre ;
Montoto-Grillot, Christine ;
Ducreux, Michel .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825
[5]   Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer [J].
Cunningham, David ;
Chau, Ian ;
Stocken, Deborah D. ;
Valle, Juan W. ;
Smith, David ;
Steward, William ;
Harper, Peter G. ;
Dunn, Janet ;
Tudur-Smith, Catrin ;
West, Julia ;
Falk, Stephen ;
Crellin, Adrian ;
Adab, Fawzi ;
Thompson, Joyce ;
Leonard, Pauline ;
Ostrowski, Joe ;
Eatock, Martin ;
Scheithauer, Werner ;
Herrmann, Richard ;
Neoptolemos, John P. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) :5513-5518
[6]  
DePamphilis M.L., 1996, DNA Replication in Eukaryotic Cells
[7]   Response to Combined Molecular Targeting: Defining the Role of P-STAT3 [J].
Egloff, Ann Marie ;
Grandis, Jennifer R. .
CLINICAL CANCER RESEARCH, 2011, 17 (03) :393-395
[8]  
El-Rayes Basil F, 2003, Clin Adv Hematol Oncol, V1, P430
[9]   A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma [J].
Farnell, MB ;
Pearson, RK ;
Sarr, MG ;
DiMagno, EP ;
Burgart, LJ ;
Dahl, TR ;
Foster, N ;
Sargent, DJ .
SURGERY, 2005, 138 (04) :618-628
[10]   Meta-analysis of randomized trials: Evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer [J].
Heinemann, Volker ;
Boeck, Stefan ;
Hinke, Axel ;
Labianca, Roberto ;
Louvet, Christophe .
BMC CANCER, 2008, 8 (1)